Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 17 (6), 593-609

Investigational Drugs in Recent Clinical Trials for Treatment-Resistant Depression

Affiliations
Review

Investigational Drugs in Recent Clinical Trials for Treatment-Resistant Depression

Ricardo P Garay et al. Expert Rev Neurother.

Abstract

The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future. Areas covered: Sixty-two trials were identified in US and EU clinical trial registries that included six investigational compounds in recent phase III development and 12 others in recent phase II clinical trials. Glutamatergic agents have been the focus of many studies. A single intravenous dose of the glutamatergic modulator ketamine produces a robust and rapid antidepressant effect in persons with TRD; this effect continues to remain significant for 1 week. This observation was a turning point that opened the way for other, more selective glutamatergic modulators (intranasal esketamine, AVP-786, AVP-923, AV-101, and rapastinel). Of the remaining compounds, monoclonal antibodies open highly innovative therapeutic options, based on new pathophysiological approaches to depression. Expert commentary: Promising new agents are emerging for TRD treatment. Glutamatergic modulators likely represent a very promising alternative to monoaminergic antidepressant monotherapy. We could see the arrival of the first robust and rapid acting antidepressant drug in the near future, which would strongly facilitate the ultimate goal of recovery in persons with TRD.

Keywords: AV-101; AVP-786; brexpiprazole; buprenorphine; cariprazine; clinical trials; esketamine; ketamine; rapastinel; treatment-resistant depression.

Figures

Figure 1
Figure 1
Status of investigational drugs in recent phase II/III clinical trials for TRD. *FDA-approved as an adjunctive therapy to antidepressants for the treatment of major depressive disorder.

Similar articles

See all similar articles

Cited by 13 PubMed Central articles

See all "Cited by" articles

MeSH terms

Feedback